NDC product
Doxylamine succinate and pyridoxine hydrochloride
NDC 0591-2132 · Actavis Pharma, Inc.
Key facts
| Product NDC | 0591-2132 |
|---|---|
| Proprietary name | Doxylamine succinate and pyridoxine hydrochloride |
| Nonproprietary name | Doxylamine succinate and pyridoxine hydrochloride |
| Substances | DOXYLAMINE SUCCINATE, PYRIDOXINE HYDROCHLORIDE |
| Dosage form | TABLET, DELAYED RELEASE |
| Route | ORAL |
| Labeler | Actavis Pharma, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA205811 |
| Pharmacologic classes | Analogs/Derivatives [Chemical/Ingredient], Antihistamine [EPC], Histamine Receptor Antagonists [MoA], Vitamin B 6 [Chemical/Ingredient], Vitamin B6 Analog [EPC] |
| Marketing start | Jun 21, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: